Letter: tenofovir versus entecavir for hepatocellular carcinoma prevention in chronic hepatitis B-related compensated cirrhosis

Aliment Pharmacol Ther. 2021 May;53(9):1040-1041. doi: 10.1111/apt.16273.

Authors

Rui Huang¹, Jiacheng Liu², Jian Wang¹, Chao Wu¹

Affiliations

¹ Department of Infectious Diseases, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China.
² Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China.

PMID: 33831236
DOI: 10.1111/apt.16273

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Carcinoma, Hepatocellular* / prevention & control
Guanine / analogs & derivatives
Hepatitis B, Chronic* / complications
Hepatitis B, Chronic* / drug therapy
Hepatitis B, Chronic* / prevention & control
Humans
Liver Cirrhosis / drug therapy
Liver Cirrhosis / prevention & control
Liver Neoplasms* / prevention & control
Taiwan
Tenofovir / therapeutic use

Substances

entecavir
Guanine
Tenofovir